Biology DivisionSection of Animal Resources

Publications

A cancer-specific monoclonal antibody against HER2 exerts antitumor activities in human breast cancer xenograft models.
M. K. Kaneko., H. Suzuki, T. Ohishi, T. Nakamura, T. Tanaka, and Y. Kato.
Int. J. Mol. Sci., 2024, 25, 1941.

A cancer-specific monoclonal antibody against podocalyxin exerted antitumor activities in pancreatic cancer xenografts.
H. Suzuki, T. Ohishi, T. Tanaka, M. K. Kaneko, and Y. Kato.
Int J. Mol. Sci., 2024, 25, 161.

Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
T. Arimori , E. Mihara, H. Suzuki, T. Ohishi, T. Tanaka, M. K. Kaneko, J.Takagi, and Y. Kato.
Structure, 2024, 536-549.e5.

Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.
G. Li, H. Suzuki, T. Ohishi, T. Asano, T. Tanaka, M. Yanaka, T. Nakamura, T. Yoshikawa, M. Kawada, M. K. Kaneko, and Y. Kato.
Int. J. Mol. Med., 2023, 51, 18.

Effects of epigallocatechin-3-gallate on matrix metalloproteinases in terms of its anticancer activity.
H. Tanabe, T. Suzuki, T. Ohishi, M. Isemura, Y. Nakamura, and K. Unno.
Molecules, 2023, 28, 525.

A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.
S. Takase, T. Hiroyama, F. Shirai, Y. Maemoto, A. Nakata, M. Arata, S. Matsuoka, T. Sonoda, H. Niwa, S. Sato, T. Umehara, M. Shirouzu, Y. Nishigaya, T. Sumiya, N. Hashimoto, R. Namie, M. Usui, T. Ohishi, S. Ohba, M. Kawada, Y. Hayashi, H. Harada, T. Yamaguchi, Y. Shinkai, Y. Nakamura, M. Yoshida, and A. Ito.
Nat. Commun., 2023, 14, 23.

Current targeted therapy for metastatic colorectal cancer.
T. Ohishi, M. K. Kaneko, Y. Yoshida, A. Takashima, Y. Kato, and M. Kawada.
Int. J. Mol. Sci., 2023, 24, 1702.

がんエネルギー代謝を標的とした創薬
吉田潤次郎、大石智一、川田学
腫瘍内科, 2023, 31, 102-108.

Pancreatic stromal cell-derived oncostatin M confers drug resistance to a multi-tyrosine kinase inhibitor in pancreatic cancer cells.
D. Tatsuda, J. Yoshida, T. Ohishi, and M. Kawada.
Anticancer Res., 2023, 43, 2477-2489.

Anti-inflammatory effects of dietary polyphenols through Inhibitory activity against metalloproteinases.
T. Suzuki, T. Ohishi, H. Tanabe, N. Miyoshi, and Y. Nakamura.
Molecules, 2023, 28, 5426.

Defucosylated monoclonal antibody (H2Mab-139-mG2a-f) exerted antitumor activities in mouse xenograft models of breast cancers against human epidermal growth factor receptor 2.
H. Suzuki, T. Ohishi, R. Nanamiya, M. Kawada, M. K. Kaneko, and Y. Kato.
Curr. Issues Mol. Biol., 2023, 45, 7734-7748.

Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling.
M. Kawatani, H. Aono, S. Hiranuma, T. Shimizu, M. Muroi, T. Nogawa, T. Ohishi, S. Ohba, M. Kawada, K. Yamazaki, S. Dan, N. Dohmae, and H. Osada.
Oncol. Res., 2023, 31, 833-844.

Pseudomonas aeruginosa theft biofilm require host lipids of cutaneous wound.
M. Sinha, N. Ghosh, D. S. Wijesinghe, S. S. M-Steiner, A. Das, K. Singh, M. El Masry, S. Khanna, H. Inoue, K. Yamazaki, M. Kawada, G. M. Gordillo, S. Roy, and C. K. Sen.
Ann. Surg., 2023, 277, e634-e647.

A humanized and defucosylated antibody against podoplanin (humLpMab-23-f) exerts antitumor activities in human lung cancer and glioblastoma xenograft models.
H. Suzuki, T. Ohishi, M. K. Kaneko, and Y. Kato.
Cancers, 2023, 15, 5080.

Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f.
T. Tanaka, H. Suzuki, T. Ohishi, M. K. Kaneko, and Y. Kato.
Cancer Sci., 2023, 115, 298-305.

Two new adenopeptins B and C inhibit sphere formation of pancreatic cancer cells.
D. Tatsuda, M. Amemiya, C. Nosaka, R. Sawa, H. Muramatsu, M. Igarashi, J. Yoshida, T. Ohishi, and M. Kawada.
J. Antibiot., 2023, 77, 73-84.

Pancreatic stromal cell-derived oncostatin M confers drug resistance to a multi-tyrosine kinase Inhibitor in pancreatic cancer cells.
D. Tatsuda, J. Yoshida, T. Ohishi, and M. Kawada.
Anticancer Res., 2023, 43, 2477-2489.

Defucosylated anti-EGFR monoclonal antibody exerted antitumor activities in mouse xenograft models of canine mammary gland tumor.
T. Tanaka, T, Ohishi, M. Saito, H. Suzuki, M. K. Kaneko, M. Kawada, and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 142-149.

A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of renal cell cancers.
H. Kawabata, T. Ohishi, H. Suzuki, T. Asano, M. Kawada, H. Suzuki, M. K. Kaneko and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 320-327.

A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of CD10-overexpressed tumors.
H. Kawabata, H. Suzuki, T. Ohishi, M. kawada, M. K. Kaneko and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2023, 41, 59-66.

Antitumor activities in mouse xenograft models of canine mammary gland tumor by defucosylated mouse-dog chimeric anti-EGFR antibody (E134Bf).
G. Li, H. Suzuki, J. Takei, T. Asano, M. Sano, T. Tanaka, H. Harada, T. Mizuno, T. Ohishi, M. Kawada, M. K. Kaneko and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 53-58.

Antitumor activities in mouse xenograft models of canine fibroblastic tumor by defucosylated anti-EGFR monoclonal antibody.
N. Goto, H. Suzuki, T. Ohishi, A. Harakawa, G. Li, M. Saito, J. Takei, T. Tanaka, T. Asano, M. Sano, M. Kawada, M. Kaneko, and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 67-73.

Rediscovery of 4-trehalosamine as a biologically stable, mass-producible, and chemically modifiable trehalose analog.
S. Wada, H. Arimura, M. Nagayoshi, R. Sawa, Y. Kubota, K. Matoba, C. Hayashi, Y. Shibuya, M. Hatano, Y. Takehana, S. Ohba, Y. Kobayashi, T. Watanabe, M. Shibasaki, and M. Igarashi.
Adv. Sci., 2022, 6, 2101309.

Involvement of microRNA modifications in anticancer effects of major polyphenols from green tea, coffee, wine, and curry.
T. Ohishi, S. Hayakawa and N. Miyoshi.
Crit. Rev. Food Sci. Nutr., 2022, 63, 7148-7179.

TrMab-6 exerts antitumor activity in mouse xenograft models of breast cancers.
T. Tanaka, T. Ohishi, M. Saito, M. Kawada, M. K. Kaneko and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 32-38.

Defucosylated anti-EGFR monoclonal antibody (134-mG2a-f) exerts antitumor activities in mouse xenograft models of canine osteosarcoma.
R. Nanamiya, J. Takei, T. Ohishi, T. Asano, T. Tanaka, M. Sano, T. Nakamura, M. Yanaka, S. Handa, Y. Komatsu, H. Hosono, N. Tateyama, Y. Harigae, M. Saito, H. Suzuki, M. Kawada, M. K. Kaneko and Y. Kato.
Monoclon Antib Immunodiagn Immunother., 2022, 41, 1-7.

Antitumor activities in mouse xenograft models of canine fibroblastic tumor by defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf).
H. Suzuki, T. Asano, T. Ohishi, T. Yoshikawa, H. Suzuki, T. Mizuno, T. Tanaka, M. Kawada, M. K. Kaneko, and Y. Kato.
Monoclon. Antib. Immunodiagn. Immunother., 2022, 42, 34-40.

Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
T. Ohishi, T. Hishiki, M. S. Baig, S. Rajpoot, U. Saquib, T. Takasaki, and Y. Hara.
PLoS One, 2022, 17, e0271112.

Health effects of soy isoflavones and green tea catechins on cancer and cardiovascular diseases based on urinary biomarker levels.
T. Ohishi, N. Miyoshi, M. Mori, M. Sagara, and Y. Yamori.
Molecules, 2022, 27, 8899.

Contribution of non-coding RNAs to anticancer effects of dietary polyphenols: chlorogenic acid, curcumin, epigallocatechin-3-gallate, genistein, quercetin and resveratrol.
S. Hayakawa, T. Ohishi, Y. Oishi, M. Isemura, and N. Miyoshi.
Antioxidants, 2022, 11, 2352.

A defucosylated anti-EpCAM monoclonal antibody (EpMab-37-mG2a-f) exerts antitumor activity in xenograft model.
T. Asano, T. Tanaka, H. Suzuki, G. Li, T. Ohishi, M. Kawada, T. Yoshikawa, M. K. Kaneko, and Y. Kato.
Antibodies, 2022, 11, 74.

Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf) exerts antitumor activities in mouse xenograft models of canine osteosarcoma.
R. Nanamiya, T. Ohishi, H. Suzuki, T. Mizuno, T. Yoshikawa, T. Asano, T. Tanaka, M. K. Kaneko, and Y. Kato.
Monoclon. Antib. Immunodiagn. Immunother., 2022, 42, 27-33.

Antitumor activity of an anti-EGFR/HER2 bispecific antibody in a mouse xenograft model of canine osteosarcoma.
N. Tateyama, H. Suzuki, T. Ohishi, T. Asano, T. Tanaka, T. Mizuno, T. Yoshikawa, M. Kawada, M. K. Kaneko, and Y. Kato.
Pharmaceutics, 2022, 14, 2494.

Anti-lung cancer properties of cyanobacterial bioactive compounds.
M. S. Baig, S. Rajpoot, T. Ohishi, R. Savai, S. Seidel, N. A. Kamennaya, E. E. Bezsonov, A. N. Orekhov, P. Mahajan, K. Solanki, and U. Saqib.
Arch. Microbiol., 2022, 204, 603.

Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
K. Solanki, S. Rajpoot, A. Kumar, K. Y J Zhang, T. Ohishi, N. Hirani, K. Wadhonkar, P. Patidar, Q. Pan, and M. S Baig.
Future Virol., 2022, 10-2217.

Defucosylated mouse‑dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.
H. Suzuki, T. Ohishi, T. Asano, T. Tanaka, M. Saito, T. Mizuno, T. Yoshikawa, M. Kawada, M. K. Kaneko, and Y. Kato.
Oncol. Rep., 2022, 48, 154.

Anti-cancer effects of dietary polyphenols via ROS-mediated pathway with their modulation of microRNAs.
Y. Yoshioka, T. Ohishi, Y. Nakamura, R. Fukutomi and N. Miyoshi.
Molecules, 2022, 27, 3816.

Mitochondrial complex I inhibitors suppress tumor growth through concomitant acidification of the intra- and extracellular environment
J. Yoshida, T. Ohishi, H. Abe, S. Ohba, H. Inoue, I. Usami, M. Amemiya, R. Oriez, C. Sakashita, S. Dan, M. Sugawara, T. Kawaguchi, J. Ueno, Y. Asano, A. Ikeda, M. Takamatsu, G. Amori, Y. Kondoh, K. Honda, H. Osada, T. Noda, T. Watanabe, T. Shimizu, M. Shibasaki, M. Kawada.
iScience 24, 103497 December 17, 2021 ª 2021 The Author(s). https://doi.org/10.1016/ j.isci.2021.103497

Identification of dihydroorotate dehydrogenase inhibitors-indoluidins-that inhibit cancer cell growth.
M. Kawatani, H. Aono, T. Shimizu, S. Ohkura, S. Hiranuma, M. Muroi, N. Ogawa, T. Ohishi, SI. Ohba, M. Kawada, K. Yamazaki, S. Dan and H. Osada
ACS Chem. Biol. 2021 Acpepted doi: 10.1021/acschembio.1c00625

An anti-TROP2 monoclonal antibody TrMab-6 exerts antitumor activity in breast cancer mouse xenograft models
T. Tanaka, T. Ohishi, T. Asano, J. Takei, R. Nanamiya , H. Hosono, M. Sano, H. Harada, M. Kawada, M. K. Kaneko and Y. Kato
Oncol Rep., 2021, 46(1), 132, doi: 10.3892/or.2021.8083.

Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
T. Asano, T. Ohishi, J. Takei, T. Nakamura, R. Nanamiya, H. Hosono, T.Tanaka, M. Sano, H. Harada, M. Kawada, M. K. Kaneko and Y. Kato
Oncol Rep., 46(2), 173, doi: 10.3892/or.2021.8124.(2021)

「がんと間質の相互作用を標的とした薬剤開発の現状」
大石智一，吉田潤次郎，川田　学
実験医学増刊, 2021, 39, 12, 147-153.

The therapeutic potential of mitochondrial toxins.
M. Kawada, M. Amemiya, J. Yoshida and T. Ohishi
J. Antibiot., 2021, 74, 696-705.

Androprostamine A: a unique antiprostate cancer agent.
Y. Yamazaki, H. Abe, C. Sakashita, SI. Ohba, T. Watanabe, I. Momose and M. Kawada.
J. Antibiot., 2021, 74, 717-725.

An Anti-HER2 monoclonal antibody H 2 mab-41 exerts antitumor activities in mouse xenograft model using dog HER2-overexpressed cells.
N. Tateyama, T. Asano, T. Ohishi, J. Takei, H. Hosono, R. Nanamiya, T. Tanaka, M. Sano, M. Saito, M. Kawada, M. K. Kaneko and Y. Kato
Monoclon. Antib. Immunodiagn. Immunother., 2021, 40, 184-190.

Defucosylated anti-epidermal growth factor receptor monoclonal antibody 134-mG2a-f exerts antitumor activities in mouse xenograft models of dog epidermal growth factor receptor-overexpressed cells.
N. Tateyama, R. Nanamiya, T. Ohishi, J. Takei, T. Nakamura, M. Yanaka, H. Hosono, M. Saito, T. Asano, T. Tanaka, M. Sano, M. Kawada, M. K. Kaneko and Y. Kato
Monoclon. Antib. Immunodiagn. Immunother., 2021, 40, 177-183.

A novel therapeutic peptide blocks SARS-CoV-2 spike protein binding with host cell ACE2 receptor.
S. Rajpoot, T. Ohishi, A. Kumar, Q. Pan, S. Banerjee, Kam Y. J. Zhang and Mirza S. Baig
Drugs R D., 2021, 21, 273-283.

Identification of a small-molecule glucose transporter inhibitor, glutipyran, that inhibits cancer cell growth.
M. Kawatani, H. Aono, S. Hiranuma, T. Shimizu, M. Muroi, N. Ogawa, T. Ohishi, S.-I. Ohba, M. Kawada, T. Nogawa, A. Okano, D. Hashizume and H. Osada
ACS Chem. Biol., 2021, 16, 1576-1586.

Beneficial effects of epigallocatechin-3-O-gallate, chlorogenic acid, resveratrol and curcumin on neurodegenerative diseases.
R. Fukutomi, T. Ohishi, Y. Koyama, M. Pervin, Y. Nakamura and M. Isemura
Molecules, 2021, 26, 415.

The Beneficial Effects of Principal Polyphenols from Green Tea, Coffee, Wine, and Curry on Obesity.
T. Ohishi, R. Fukutomi, Y. Shoji, S. Goto and M. Isemura
Molecules, 2021, 26, 453.

Tumor-derived exosomes in the regulation of macrophage polarization.
MS. Baig, A. Roy, S. Rajpoot, D. Liu, R. Savai, S. Banerjee, M. Kawada, SM. Faisal, R. Saluja, U. Saqib, T. Ohishi and KK. Wary.
Inflamm Res. 2020, 69, 435-451

H2Mab-19 anti-human epidermal growth factor receptor 2 monoclonal antibody therapy exerts antitumor activity in pancreatic cancer xenograft models.
Y. Kato, T. Ohishi, M. Sano, T. Asano, Y. Sayama, Y. Takei, M. Kawada and MK. Kaneko
Monoclon Antib Immunodiagn Immunother., (2020) doi: 10.1089/mab.2020.0011.

An anti-human epidermal growth factor receptor 2 monoclonal antibody H2Mab-19 exerts antitumor activity in mouse colon cancer xenografts.
Y. Kato, T. Ohishi, J. Takai, T. Nakamura, M. Sano, T. Asano, Y. Sayama, H. Hosono, M. Kawada and MK. Kaneko
Monoclon Antib Immunodiagn Immunother., (2020) doi: 10.1089/mab.2020.0009

Interferon-induced transmembrane protein 1 (IFITM1) promotes distant metastasis of small cell lung cancer.
S. Sakamoto, H. Inoue, Y. Kohda, S. Ohba, T. Mizutani, and M. Kawada
Int. J. Mol. Sci., 2020, Vol. 21, 4934.

An antihuman epidermal growth factor receptor 2 monoclonal antibody (HMab-19) exerts antitumor activity in glioblastoma xenograft models.
Y. Kato, T. Ohishi, J. Takei, T. Nakamura, M. Kawada and MK. Kaneko
Monoclon. Antibodies Immunodiagn. Immunother., 39(4),2020, doi: 10.1089/mab.2020.0013

H 2 Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts.
J. Takei, MK. Kaneko, T. Ohishi, M. Kawada, H. Harada and Y. Kato
Exp. Ther. Med., 2020, 20(2), 846-853.

Anti-metastatic activity of an anti-EGFR monoclonal antibody against metastatic colorectal cancer with KRAS p.G13D mutation.
T. Ohishi, Y. Kato, MK. Kaneko, SI. Ohba, H. Inoue, A. Harakawa and M. Kawada
Int. J. Mol. Sci., 21(17):E6037 (2020)

The anti-EGFR monoclonal antibody 134-mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
H. Hosono, J. Takei, T. Ohishi, M. Sano, T. Asano, Y. Sayama, T. Nakamura, M. Yanaka, M. Kawada, H. Harada, MK. Kaneko and Y. Kato
Int. J. Mol. Med., 46(4), 1443-1452, 2020

Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas.
M. K. Kaneko, T. Ohishi, J. Takei, M. Sano, T. Nakamura, H. Hosono, M. Yanaka, T. Asano, Y. Sayama, H. Harada, M. Kawada and Y. Kato
Oncol Rep., 2020, 44(6), 2517-2526.

A defucosylated anti-PD-L1 monoclonal antibody 13-mG 2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
J. Takei, T. Ohishi, M. K. Kaneko, H. Harada, M. Kawada and Y. Kato
Biochem Biophys Rep., 24:100801 (2020)

Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.
T. Onodera, I. Momose, H. Adachi, Y. Yamazaki, R. Sawa, SI. Ohba and M. Kawada
J. Biol. Chem., 2020, 295, 16678-16690.

A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
J. Takei, M. K. Kaneko, T. Ohishi, H. Hosono, T. Nakamura, M. Yanaka, M. Sano, T. Asano, Y. Sayama, M. Kawada, H. Harada and Y. Kato
Oncol. Rep., 2020, 44(5), 1949-1960.

Anti-cancer effects of green tea epigallocatchin-3-gallate and coffee chlorogenic acid
S. Hayakawa, T. Ohishi, N. Miyoshi, Y. Oishi, Y. Nakamura and M. Isemura
Molecules, 25(19):E4553., (2020)

Development of core-fucose-deficient humanized and chimeric anti-human podoplanin antibodies.
M. K. Kaneko, T. Ohishi, T. Nakamura, H. Inoue, J. Takei, M. Sano, T. Asano, Y. Sayama, H. Hosono, H. Suzuki, M. Kawada and Y. Kato
Monoclon. Antibodies Immunodiagn. Immunother., 2020, 39(5), 167-174.

A cancer-specific anti-podocalyxin monoclonal antibody (60-mG 2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma
M. K. Kaneko, T. Ohishi, M. Kawada and Y. Kato
Biochem. Biophys. Rep., 2020, 24, 100826.

The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
H. Hosono, T. Ohishi, J. Takei, T. Asano, Y. Sayama, M. Kawada, M. K. Kaneko, Y. Kato
Oncol Lett., 2020, 20, 383.

Antibody-drug conjugates using mouse-canine chimeric anti-dog podoplanin antibody exerts antitumor activity in a mouse xenograft model.
Y. Kato, Y. Ito, T. Ohishi, M. Kawada, T. Nakamura, Y. Sayama, M. Sano, T. Asano, M. Yanaka, S. Okamoto, S. Handa, Y. Komatsu, J. Takei and MK. Kaneko.
Monoclon Antib Immunodiagn Immunother., 2020, 39, 37-44

Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis
A. Leesombun, M. Iijima, K. Umeda, D. Kondoh, B. Pagmadulam, A. M Abdou, Y. Suzuki, S. Ohba, K. Isshiki, T. Kimura, Y. Kubota, R. Sawa, CI. Nihei, Y. Nishikawa.
The Journal of Infectious Diseases, 2020, 221, 766-774

Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.
Y. Kato, T. Ohishi, S. Yamada, S. Itai, Y. Furusawa, M. Sano, T. Nakamura, M. Kawada and MK. Kaneko
Monoclon. Antib. Immunodiagn. Immunother. 2019, doi:10.1089/mab.2019.0002.

The mouse–canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Y. Kato, T. Ohishi, M. Kawada, N. Maekawa, S. Konnai, S. Itai, S. Yamada and MK. Kaneko
Biochem Biophys Rep.　2019, 17, 23-26

Identification of a small compound targeting PKM2-regulated signaling using 2D gel electrophoresis-based proteome-wide CETSA
I. Nagasawa, M. Muroi, M. Kawatani, T. Ohishi, S. Ohba, M. Kawada and H. Osada
Cell Chem. Biol., 2020, 27, 186-196.

A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
J. Takei, MK. Kaneko, T. Ohishi, M. Kawada, H. Harada and Y. Kato
Oncol. Lett., 2020, 19, 2809-2816.

Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced insulin-like growth factor-1 secretion by prostate stromal cells.
T. Ohishi, H. Abe, C. Sakashita, U. Saqib, MS. Baig, SI. Ohba, H. Inoue, T. Watanabe, M. Shibasaki and M. Kawada.
nt J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32959.

Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.
Y. Kato, T. Ohishi, S. Yamada, S. Itai, J. Takei, M. Sano, T. Nakamura, H. Harada, M. Kawada and MK. Kaneko
Monoclon. Antib. Immunodiagn. Immunother., 2019, 38, 157-161.

Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy
S. Sakamoto, H. Inoue, M. K. Kaneko, S. Ogasawara, M. Kajikawa, S. Urano, S. Ohba, Y. Kato and M. Kawada
Cancer Sci., 2019, 110, 3595-3602.

Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B.
T. Hatta, SI. Iemura, T. Ohishi, H. Nakayama, H. Seimiya, T. Yasuda, K. Iizuka, M. Fukuda, J. Takeda, T. Natsume and Y. Horikawa.
Sci Rep. 2018, 8:16756, doi: 10.1038/s41598-018-35204-x.

Dihydroorotate dehydrogenase as a target for the development of novel Helicobacter pylori-specific antimicrobials.
T. Ohishi, DK. Inaoka, K. Kita and M. Kawada
Chem. Pharm. Bull. 2018, 66, 1-4

MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs
K. Okamoto, T. Ohishi, M. Kuroiwa, S. Iemura, T. Natsume and H. Seimiya
Oncotarge 2018, 9, 35844-35855

Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.
S. Itai, S. Yamada, M. Kaneko, M. Sano, T. Nakamura, M. Yanaka, S. Handa, K. Hisamatsu, Y. Nakamura, Y. Furusawa, M. Fukui, T. Ohishi, M. Kawada, H. Harada and Y. Kato
Biochem Biophys Rep. 2018, 15, 93-96

Beneficial effects of green tea catechins on neurodegenerative diseases.
M. Pervin, K. Unno, T. Ohishi, H. Tanabe, N. Miyoshi and Y. Nakamura
Molecules 2018, 23, 1297

Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
S. Itai, T. Ohishi, MK. Kaneko, S. Yamada, S. Abe, T. Nakamura, M. Yanaka, YW. Chang, SI. Ohba, Y. Nishioka, M. Kawada, H. Harada and Y. Kato
Oncotarget 2018, 9, 22480-22497

Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.
T. Ohishi, T. Masuda, H. Abe, C. Hayashi, H. Adachi, S. Ohba, M. Igarashi, T. Watanabe, H. Mimuro, E. Amalia, DK. Inaoka, K. Mochizuki, K. Kita, M. Shibasaki and M. Kawada
Helicobacter 2018, 23, e12470

In vivo efficacy of β-lactam/tripropeptin C in a mouse septicemia model and the mechanism of reverse β-lactam resistance in methicillin-resistant Staphylococcus aureus mediated by tripropeptin C.
H. Hashizume1, Y. Takahashi, T. Masuda, S. Ohba, T. Ohishi, M. Kawada and M. Igarashi
J. Antibiot. 2018, 71, 79-85

Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion.
T. Ohishi, H. Yoshida, M. Katori, T. Migita, Y. Muramatsu, M. Miyake, Y. Ishikawa, A. Saiura, SI. Iemura, T. Natsume and H. Seimiya
Cancer Res. 2017, 77, 2328-2338

Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.
T. Migita, A. Ueda, T. Ohishi, M. Hatano, H. Seimiya, S. Horiguchi, F. Koga and F. Shibasaki.
Laboratory Investigation 2017, 97, 567-576

Antipodocalyxin antibody chPcMab-47 exerts antitumor activity in mouse xenograft models of colorectal adenocarcinomas.
MK. Kaneko, A. Kunita, S. Yamada, T. Nakamura, M. Yanaka, N. Saidoh, YW. Chang, S. Handa, S. Ogasawara, T. Ohishi, S. Abe, S. Itai, H. Harada, M. Kawada, Y. Nishioka, M. Fukayama and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2017, 36, 157-162

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo
M. Kawada, H. Inoue, M. Kajikawa, M. Sugiura, S. Sakamoto, S. Urano, C. Karasawa, I. Usami, M. Futakuchi and T. Masuda.
Sci. Rep. 2017, 7:40400 doi: 10.1038/srep40400.

Anti-inflammatory action of green tea.
T. Ohishi, S. Goto, P. Monira, M. Isemura and Y. Nakamura.
Antiinflamm Antiallergy Agents Med Chem. 2016, 15, 74-90.

SF-1 deficiency causes lipid accumulation in Leydig cells via suppression of STAR and CYP11A1.
M. Hatano, T. Migita, T. Ohishi, Y. Shima, Y. Ogawa, Kl. Morohashi, Y. Hasegawa and F. Shibasaki.
Endocrine. 2016, 54, 484-496.

Anti-cancer effects of green tea by either anti- or pro-oxidative mechanisms.
S. Hayakawa, K. Saito, N. Miyoshi, T. Ohishi, Y. Oishi, Y. Oishi, M. Miyoshi and Y. Nakamura
Asian Pac J Cancer Prev. 2016, 17, 1649-1654.

Bladder cancer stem-like cells: their origin and therapeutic perspectives.
T. Ohishi, F. Koga and T. Migita.
Int. J. Mol. Sci. 2016, 17, 43

Report on the use of non-clinical studies in the regulatory evalution of oncology drugs.
Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
Cancer Sci. 2016,107,189-202.

Novel autophagy inducers lentztrehaloses A, B and C
S. Wada, Y. Kubota, R. Sawa, M. Umekita, M. Hatano, S. Ohba, C. Hayashi, M. Igarashi and A. Nomoto.
J. Antibiot. 2015, 68, 521-529

New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
S. Sakamoto, H. Inoue, S. Ohba, Y. Kohda, I. Usami, T. Masuda, M. Kawada and A. Nomoto.
Cancer Science.2015 106，367-374

Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors.
I. Momose, H. Abe, T. Watanabe, S. Ohba, K. Yamazaki, S. Dan, T. Yamori, T. Masuda and
A. Nomoto
Cancer Sci. 2014, 105, 1609-1615.

Structure and biological properties of lentztrehalose: a novel trehalose analog.
S. Wada, S. Ohba, T. Someno, M. Hatano and A. Nomoto.
J. Antibiot. 2014, 67, 319-322.

Suppression of type II collagen-induced arthritis by ICM0301B, a new angiogenesis inhibitor.
H. Kumagai, T. Masuda, S. Ohba and D. Ikeda.
J. Antibiot. 2013, 66, 243-246.

Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents.
H. Abe, M. Kawada, H. Inoue, S. Ohba, A. Nomoto, T. Watanabe and M. Shibasaki.
Org. Lett. 2013, 15, 2124-2127.

Structure-activity relationship study of intervenolin derivatives:
synthesis, antitumor and anti-Helicobacter Pylori activities.
H. Abe, M. Kawada, H. Inoue, S. Ohba, T. Masuda, C. Hayashi, M. Igarashi,
A. Nomoto, T. Watanabe and M. Shibasaki.
Tetrahedron 2013, 69, 7608-7617.

Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.
M. Kawada, H. Inoue, S. Ohba, M. Hatano, M. Amemiya, C. Hayashi, I. Usami, H. Abe, T. Watanabe, N. Kinoshita, M. Igarashi, T. Masuda, D. Ikeda and A. Nomoto.
J. Antibiot. 2013, 66, 543-548.

Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
R. Sawa, Y. Takahashi, H. Hashizume, K. Sasaki, Y. Ishizaki, M.Umekita, M. Hatano,
H. Abe, T. Watanabe, N. Kinoshita, Y. Homma, C. Hayashi, K. Inoue, S. Ohba,
T. Masuda, M. Arakawa, Y. Kobayashi, M. Hamada, M. Igarashi, H. Adachi,
Y. Nishimura and Y. Akamatsu.
Chem. Eur. J. 2012, 18, 15772-15781.

In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
I. Momose, D. Tatsuda, S. Ohba, T. Masuda, D. Ikeda and A. Nomoto.
Cancer Sci. 2012, 103, 1730-1736.

Citric acid inhibits a bacterial ceramidase and alleviates atopic dermatitis in an animal model.
H. Inoue, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2010, 63, 611-613.

NBRI16716A, a new antitumor compound against human prostate cancer cells, produced by Perisporiopsis melioloides Mer-f16716.
M. Kawada, T. Someno, H. Inoue, S. Ohba, T. Masuda, T. Kato and D. Ikeda.
J. Antibiot. 2010, 63, 319-323.

NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671.
M. Kawada, I. Usami, T. Someno, T. Watanabe, H. Abe, H. Inoue, S. Ohba, T. Masuda,
Y. Tabata, S. Yamaguchi and D. Ikeda.
J. Antibiot. 2010, 63, 237-243.

Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
I. Momose, S. Ohba, D. Tatsuda, M. Kawada, T. Masuda, G. Tsujiuchi, T. Yamori, H. Esumi and D. Ikeda.
Biochem. Biophys. Res. Commun. 2010, 392, 460-466.

Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
S. Wada, I. Usami, Y. Umezawa, H. Inoue, S. Ohba, T. Someno, M. Kawada and D. Ikeda.
Cancer Sci. 2010, 101, 743-750.

Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells.
M. Kawada, H. Inoue, S. Ohba, T. Masuda, I. Momose and D. Ikeda.
Int. J. Cancer 2010, 126, 810-818.

Ceramidastin, a novel bacterial ceramidase inhibitor, produced by Penicillium sp.
Mer-f17067.
H. Inoue, T. Someno, T. Kato, H. Kumagai, M. Kawada and D. Ikeda.
J. Antibiot. 2009, 62, 63-67.

Phthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell interactions.
M. Kawada, H. Inoue, I. Usami and D. Ikeda.
Cancer Sci. 2009, 100, 150-157.

Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
M. Kawada, H. Inoue, M. Arakawa and D. Ikeda.
Anticancer Res. 2008, 28, 721-730.

Biology DivisionSection of Animal Resources

Publications

LABORATORIES MENU

CONTACT